Participated · Series B · Jul 2026

RapidPulse is developing a pulsed (cyclic) aspiration platform and a range of catheter sizes intended to improve clot engagement, removal efficiency and procedural consistency during mechanical thrombectomy for acute ischemic stroke. The company’s system is being evaluated in the TURBO investigational device exemption study, conducted in the United States and Europe to support its U.S. regulatory pathway. RapidPulse plans to expand clinical experience with its system across leading stroke centers as part of that program and may pursue FDA approval if clinical data support a submission. The platform strategy includes continued development of the catheter portfolio and broader clinical use to gather performance data across different patients, clot types and treatment settings. RapidPulse was spun out of medical device incubator Syntheon and is headquartered in Miami. Financially, the company recently raised an oversubscribed $48 million Series B co-led by Medtronic, TechWald Next and S3 Ventures, with additional participation from SBI Investment Company, the Florida Opportunity Fund, and existing investors.

Participated · Equity · Jul 2026

410 Medical develops advanced resuscitation technologies centered on its lead product, the LifeFlow infuser, which received FDA clearance in 2016. LifeFlow is used by more than 500 hospitals and EMS agencies and has been used to treat nearly 80,000 patients experiencing conditions like sepsis and hemorrhagic shock. The company was founded in 2013 and is based in North Carolina. In July 2026 410 Medical raised $12 million in growth financing led by Orlando Health Ventures to scale commercial operations and accelerate LifeFlow adoption. The company is also investing in a next-generation LifeFlow device planned for launch in 2027. The financing was supported by a syndicate of hospital and healthcare investors, reflecting continued commercial momentum.

Participated · Seed · Jun 2026

Ladder Health delivers virtual-first, AI-enabled developmental and therapeutic care for children, providing speech, occupational, physical, and feeding therapy through a model that activates caregivers as therapeutic partners. The platform offers evenings and weekends access and emphasizes extending care into the home to reduce wait times from months to days. Ladder partners with pediatric practices and health systems as a referral and care-extension partner and reports working with more than 80 provider organizations and health systems across Massachusetts, North Carolina, and Maryland. The company was incubated by 25madison and developed in collaboration with clinical experts at Boston Children's Hospital, which holds equity in Ladder. Current plans highlighted by the company include geographic expansion into additional states and continued investment in its AI-enabled care platform and health system integrations. Ladder positions its model as a scalable response to pediatric workforce shortages and the surge in demand for developmental services.

Led · Series B · May 2026

CREATE Medicines develops in vivo immune programming therapies by delivering proprietary mRNA-LNP constructs that directly engineer T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. Its lead autoimmune program, CRT-402, is a next-generation CD19 targeted in vivo CAR-T candidate with demonstrated deep and durable B cell depletion in non-human primates and designed for repeat dosing; the company is also advancing a dual CAR CD19 x BCMA program to broaden reach across refractory autoimmune indications. In oncology, CREATE is advancing multiple programs, including MT-303, which has shown compelling early clinical responses in frontline hepatocellular carcinoma. The company reports dosing more than 50 patients across its in vivo CAR clinical programs, which it cites as the largest clinical dataset in the field. CREATE highlights integration of clinically validated CAR architectures, optimized RNA design, targeted delivery technologies, and ownership of manufacturing infrastructure as core competitive advantages. Recent leadership additions include Ron Philip as Executive Chairman and new board members from ARCH Venture Partners and Newpath Partners.

Led · Series B · Apr 2026

Incyclix Bio is advancing INX-315, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor, as its lead clinical compound. INX-315 is in a Phase 1/2 open-label, dose-escalation, combination and dose-expansion trial (NCT05735080) targeting advanced and metastatic breast and ovarian cancers, including CDK4/6 inhibitor resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors. The company positions itself as a scientific leader in understanding CDKs and their role in the cell cycle, and was founded by pioneers in CDK inhibitor discovery, research and development. Headquartered in Research Triangle Park, N.C., Incyclix is focusing resources on advancing INX-315 through clinical development with the recent Series B extension funding. No revenue or user metrics were disclosed in the announcement.